Cumberland Pharmaceuticals (NASDAQ: CPIX) reported Q2 EPS of ($0.05), $0.03 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $10.2 million versus the consensus estimate of $9.94 million.

"I am pleased to report several positive developments during the second quarter, with the most significant being the overall growth generated from our diversified portfolio of seven FDA approved brands," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "Furthermore, we continue to advance on our robust clinical pipeline, highlighted by the expected near-term NDA filing for our new methotrexate product line. We believe there is significant potential value in our clinical pipeline and its development remains a top priority for the company."

For earnings history and earnings-related data on Cumberland Pharmaceuticals (CPIX) click here.